Switching patients with inflammatory arthritis from Etanercept (Enbrel(®)) to the biosimilar drug, SB4 (Benepali(®)): A single-centre retrospective observational study in the UK and a review of the literature

OBJECTIVE/AIM: SB4 (Benepali(®)), the Etanercept biosimilar, is licenced in the UK for the same indications as the reference product, Enbrel(®). In 2016, the Rheumatology Department at Blackpool Teaching Hospitals switched the Etanercept patients, who gave consent, to SB4. A proportion of these pati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mediterr J Rheumatol
Main Authors: Madenidou, Anastasia-Vasiliki, Jeffries, Andrew, Varughese, Sneha, Jones, Stephen, Sari-Kouzel, Hanadi, Veevers, Helen, Rao, Chandini
Formato: Artigo
Idioma:Inglês
Publicado em: The Mediterranean Journal of Rheumatology (MJR) 2019
Assuntos:
Original
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7280874/
https://ncbi.nlm.nih.gov/pubmed/32524081
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.31138/mjr.30.1.69
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados